Skip to main content
Accueil
  • fr
  • en

Main navigation

  • Company
    • Company profile
    • Management
      • Leadership Team
      • Board of Directors
    • Our history
  • Science
    • Scientific approach
    • Antibody formats
    • Publications
  • Products
    • Pipeline overview
    • ------------------
    • Lacutamab
    • IPH4502
    • Monalizumab
    • Other Clinical Stage Assets
      • IPH6501
      • IPH6101
      • IPH6401
      • IPH5201
      • IPH5301
  • Partnering
  • Investors
    • Overview
    • News
    • Events
    • Stock Info
      • Share Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Financial and Regulatory Information
      • Financial Reports
      • SEC Filings
      • Articles of Association
      • Number of Shares and Voting Rights
      • Share Repurchase Liquidity Agreement
      • Prospectus Related to Public Offering
      • Appraiser Reports
      • Regulated Agreements
    • General Shareholders Meeting
    • Governance
      • Corporate Governance
      • Management Team
    • Resources
      • Investor Email Alerts
  • Media
    • Media hub
    • All press releases
    • Media center
  • Careers
Menu

Company to host in-person and virtual event focused on IPH4502 on November 18, 2026: IPH4502 Phase 1 clinical data and development outlook


Register in-person or virtually

Lacutamab, a first-in-class antibody for cutaneous t-cell lymphoma


More about our lead asset

IPH4502, our Antibody Drug Conjugate targeting Nectin-4


More about this asset

Monalizumab (anti-NKG2A antibody), partnered with AstraZeneca


More about this asset

Collaborating with a strong network to advance our pipeline


Discover our partnering opportunities

Previous Next

About Innate Pharma

#TheFutureIsInnate

Innate Pharma is a global clinical-stage oncology-focused biotech company. Our ambition is to establish innovative approaches to make a lasting difference to patients’ lives by providing drugs based on therapeutic antibodies that harness the immune system.

See company profile

Latest news

Innate Pharma to host in-person and virtual event on IPH4502 on November 18, 2026

November 11, 2026

Innate Pharma reports third quarter 2026 business and financial update

November 5, 2026

Innate Pharma: PACIFIC-9 phase 3 trial readout timing updated to H1 2027

October 27, 2026
See all press releases

Footer

  • Contact
  • Location
  • Site map
  • Legal Info
  • Terms of use
  • Privacy Notice
  • Cookies notice
  • General Conditions of Purchase

Follow us

   

Stay in touch

 Subscribe to our newsletter

 Contact us
 

Location

117, Avenue de Luminy - BP 30191
13 009 Marseille FRANCE

+33 (0)4 30 30 30 30

 

Innate Pharma
  • Company
    • Company profile
    • Management
      • Leadership Team
      • Board of Directors
    • Our history
  • Science
    • Scientific approach
    • Antibody formats
    • Publications
  • Products
    • Pipeline overview
    • ------------------
    • Lacutamab
    • IPH4502
    • Monalizumab
    • Other Clinical Stage Assets
      • IPH6501
      • IPH6101
      • IPH6401
      • IPH5201
      • IPH5301
  • Partnering
  • Investors
    • Overview
    • News
    • Events
    • Stock Info
      • Share Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Financial and Regulatory Information
      • Financial Reports
      • SEC Filings
      • Articles of Association
      • Number of Shares and Voting Rights
      • Share Repurchase Liquidity Agreement
      • Prospectus Related to Public Offering
      • Appraiser Reports
      • Regulated Agreements
    • General Shareholders Meeting
    • Governance
      • Corporate Governance
      • Management Team
    • Resources
      • Investor Email Alerts
  • Media
    • Media hub
    • All press releases
    • Media center
  • Careers